Poliomyelitis

Poliomyelitis is an acute viral infectious disease caused by poliovirus, an enterovirus, with primary injury to anterior horn cells in the spinal cord and brainstem ^[1]. The resulting lower motor neurone cell death disrupts motor units and can lead to muscle weakness or complete paralysis ^[1]. Source-backed detail on case definition nuances, incubation, or subtype distinctions is not yet available in the provided material.

The acute disease process is described as causing lower motor neurone damage with subsequent weakness or paralysis, reflecting involvement of the motor system ^[1]. In longer-term follow-up, older survivors may experience late poliomyelitis sequelae with residual weakness that worsens with age and affects daily activities and quality of life ^[2]. Post-polio decline is reported as prevalent among people aged 60 years and over, and is characterized primarily by fatigability and muscle weakness; pain is also common ^[1]. Reported functional consequences include impaired balance control, slow gait, dysfunctional lower-limb kinematics, and increased fall risk ^[1].

The World Health Organization Western Pacific Region has been polio-free for more than 20 years, indicating major regional interruption of transmission ^[2]. Nevertheless, the source material identifies two ongoing challenges: late sequelae among older survivors and the reappearance of circulating vaccine-derived poliovirus in the environment ^[2]. These vaccine-derived strains are described as having atypical genetic characteristics and reversed neurovirulence, with the ability to cause paralysis similarly to wild poliovirus and to persist through person-to-person transmission ^[2]. The provided sources do not supply broader current global incidence, country-level distribution, or detailed outbreak counts.

Poliovirus is an infectious agent that can spread person-to-person, and the source material specifically notes that circulating vaccine-derived strains may persist in the environment and maintain transmission chains ^[2]. Beyond this, source-backed detail on the exact transmission route, infectious dose, or environmental survival is not yet available in the provided material.

Source-backed higher-concern groups include elderly poliomyelitis survivors, among whom late sequelae and post-polio decline are reported ^[2][1]. People aged 60 years and over are specifically mentioned in relation to postpolio decline ^[1]. The material also indicates that individuals exposed to poliovirus are protected by immunization, implying that people with declining immunity are at greater risk of reemergence-related disease, but more detailed risk stratification is not yet available from the provided sources ^[2].

Immunization is identified as essential for preventing paralysis in exposed persons, and the sources stress the need to maintain high vaccination rates because declining immunity increases the likelihood of reemergence ^[2]. The material also calls for measures to raise immunization rates and improve living conditions in poorer nations as part of eradication efforts ^[2]. Source-backed detail on specific vaccine schedules, nonpharmaceutical interventions, or exposure-control procedures is not yet available.

In surveillance terms, poliomyelitis should be interpreted not only as a rare acute paralytic infection but also as a condition with important long-term sequelae among survivors ^[2][1]. Monitoring should remain attentive to circulating vaccine-derived poliovirus, because these strains can circulate in the environment and sustain person-to-person transmission while causing paralysis similar to wild poliovirus ^[2]. The source material also emphasizes strict observation and the maintenance of high immunization coverage as key contextual indicators for reemergence risk ^[2].

1. 1 Menant JC et al. Poliomyelitis. Handb Clin Neurol. 2018. PMID: 30482325. doi: 10.1016/B978-0-444-63916-5.00021-5. PubMed: https://pubmed.ncbi.nlm.nih.gov/30482325/
2. 2 Quarleri J et al. Poliomyelitis is a current challenge: long-term sequelae and circulating vaccine-derived poliovirus. Geroscience. 2023 Apr. PMID: 36260265. doi: 10.1007/s11357-022-00672-7. PubMed: https://pubmed.ncbi.nlm.nih.gov/36260265/
3. 3 Foster LA et al. Motor Neuron Disease: Pathophysiology, Diagnosis, and Management. Am J Med. 2019 Jan. PMID: 30075105. doi: 10.1016/j.amjmed.2018.07.012. PubMed: https://pubmed.ncbi.nlm.nih.gov/30075105/
4. 4 Poliomyelitis. Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie. 2016. doi: 10.1007/s40664-016-0090-z. DOI: https://doi.org/10.1007/s40664-016-0090-z
5. 5 POLIOMYELITIS (Anterior Poliomyelitis; Infantile Paralysis). A Synopsis of Children's Diseases. 1985. doi: 10.1016/b978-1-4831-8407-4.50027-4. DOI: https://doi.org/10.1016/b978-1-4831-8407-4.50027-4
6. 6 18 Poliomyelitis periphere Lähmungen Poliomyelitis Poliomyelitis. Neurologie für Physiotherapeuten. 2015. doi: 10.1055/b-0035-124063. DOI: https://doi.org/10.1055/b-0035-124063

ICD-10

A80

ICD-11

1C81

Total cases

32

Total deaths

1

Peak month

2011-10

Coverage

5 reporting countries · 2000-01-01 → 2026-06-01